乳癌診斷市場規模、佔有率、成長分析、按類型、產品、癌症類型、應用、最終用戶、地區 - 產業預測，2025-2032 年

預計 2023 年乳癌診斷市場規模將達到 56 億美元，並從 2024 年的 60.4 億美元成長到 2032 年的 110.1 億美元，預測期內（2025-2032 年）的複合年成長率為 7.8%。

由於迫切需要增強的檢測解決方案，乳癌診斷市場正在迅速發展。由於乳癌通常沒有早期症狀，人工智慧技術在解決患者診斷方面變得至關重要，例如 Paragon Biosciences LLC推出的 Qlarity Imaging LLC，該公司正在尋求 FDA 批准其用於乳房診斷的人工智慧系統。越來越多的公司在各種成像方式中利用人工智慧，為醫療保健提供者提供經濟高效的解決方案。印度私人診斷中心的興起，例如FUJIFILM的 NURA 健康篩檢中心，是為了滿足人們對影像診斷服務日益成長的需求，因為由於公立醫院的服務有限，私人診斷中心可以取代公立醫院。此外，在發展中地區，在西門子、通用電氣醫療和飛利浦等行業努力的支持下，整修的診斷成像設備作為一種經濟高效的選擇越來越受歡迎，以推廣高品質的再生醫學系統。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

乳癌診斷藥物市場規模（按類型）

• 市場概況
• 影像診斷
  • 乳房X光檢查
  • MRI
  • 超音波
  • PET/CT
• 切片檢查
• 基因組檢測
• 血液檢查
• 其他

乳癌診斷藥物市場規模（依產品分類）

• 市場概況
• 基於平台的產品
  • 次世代定序
  • 微陣列
  • PCR
  • 其他
• 儀器儀表類產品
  • 影像診斷
  • 切片檢查

乳癌診斷藥物市場規模（按癌症類型）

• 市場概況
• 乳管癌（乳管原位癌）
• 浸潤性乳管癌
• 發炎性乳癌
• 轉移性乳癌

乳癌診斷藥物市場規模（按應用）

• 市場概況
• 篩檢
• 診斷和預後
• 預後
• 調查
• 其他

乳癌診斷藥物市場規模（按最終用戶分類）

• 市場概況
• 醫院和診所
• 診斷中心
• 醫學研究實驗室
• 其他

乳癌診斷藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Hologic（USA）
• Natera（USA）
• Siemens Healthineers（Germany）
• Leica Biosystems（Germany）（Parent company：Danaher Corporation）
• Roche Diagnostics（Switzerland）
• GE Healthcare（USA）
• Philips Healthcare（Netherlands）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific（USA）
• Becton, Dickinson and Company（USA）
• Agilent Technologies（USA）
• Illumina（USA）
• PerkinElmer（USA）
• Qiagen（Germany）
• Bio-Rad Laboratories（USA）
• Cepheid（USA）（Parent company：Danaher Corporation）
• Myriad Genetics（USA）
• Fujifilm Holdings Corporation（Japan）
• Canon Medical Systems Corporation（Japan）
• Hitachi Medical Systems（Japan）

結論和建議

Breast Cancer Diagnostics Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.04 billion in 2024 to USD 11.01 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The breast cancer diagnostics market is evolving rapidly, driven by the urgent need for enhanced detection solutions. With breast cancer often presenting no early symptoms, AI technologies are becoming pivotal in addressing patient diagnostics, exemplified by Paragon Biosciences LLC's launch of Qlarity Imaging LLC, which aims for FDA clearance of an AI system for breast diagnostics. Companies are increasingly utilizing AI across various imaging modalities, presenting cost-effective solutions for healthcare providers. The rise of private diagnostic centers, like FUJIFILM Corporation's NURA in India, is a response to increased demand for imaging services, driven by public hospital limitations. Additionally, in developing regions, refurbished imaging equipment is gaining traction as a cost-effective alternative, supported by industry initiatives from Siemens, GE Healthcare, and Philips to promote quality refurbished systems.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Diagnostics Market Segments Analysis

Global Breast Cancer Diagnostics Market is segmented by Type, Product, Cancer Type, Application, End-user and region. Based on Type, the market is segmented into Imaging, Biopsy, Genomic Tests, Blood Tests and Others. Based on Product, the market is segmented into Platform-based Products and Instrument-based Products. Based on Cancer Type, the market is segmented into Ductal carcinoma in situ, Invasive ductal carcinoma, Inflammatory breast cancer and Metastatic breast cancer. Based on Application, the market is segmented into Screening, Diagnostic and Predictive, Prognostic, Research and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Medical Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics market is primarily driven by technological advancements, including state-of-the-art imaging techniques, molecular diagnostic methods, and biomarker assays. These innovations have greatly enhanced the accuracy and efficiency of breast cancer detection and diagnosis, leading to their widespread adoption among healthcare professionals. The continuous development of sophisticated diagnostic tools not only improves patient outcomes but also propels market growth by meeting the increasing demand for reliable and effective breast cancer screening solutions. As these technologies evolve, they further reinforce the importance of early detection and timely intervention in combating breast cancer.

Restraints in the Breast Cancer Diagnostics Market

Cultural beliefs and the social stigma associated with breast cancer can significantly hinder women's willingness to participate in screening and diagnostic tests. These factors often lead to a reluctance to seek necessary medical attention, ultimately affecting the rates of early detection and diagnosis. As a result, many women might avoid or postpone crucial evaluations due to fear, misconceptions, or societal pressures. This resistance not only increases the risk of late-stage diagnosis but also poses a challenge to the overall effectiveness of breast cancer diagnostics in improving patient outcomes. Overcoming these barriers is essential for enhancing early intervention and promoting better health practices.

Market Trends of the Breast Cancer Diagnostics Market

The breast cancer diagnostics market is witnessing a significant trend towards the adoption of liquid biopsies, which analyze circulating tumor cells and cell-free DNA from blood samples. This non-invasive approach is particularly appealing for early detection and real-time monitoring of treatment efficacy, thereby enhancing patient outcomes. As healthcare providers and patients increasingly seek alternatives to traditional tissue biopsies, the demand for liquid biopsy solutions is surging. Coupled with advancements in molecular biology and personalized medicine, this trend is expected to drive innovation, investment, and growth within the breast cancer diagnostics landscape, positioning liquid biopsies as a cornerstone in future clinical practices.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Breast Cancer Diagnostics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Imaging
  • Mammography
  • MRI
  • Ultrasound
  • PET/CT
• Biopsy
• Genomic Tests
• Blood Tests
• Others

Global Breast Cancer Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Platform-based Products
  • Next-generation Sequencing
  • Microarrays
  • PCR
  • Others
• Instrument-based Products
  • Imaging
  • Biopsy

Global Breast Cancer Diagnostics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Ductal carcinoma in situ
• Invasive ductal carcinoma
• Inflammatory breast cancer
• Metastatic breast cancer

Global Breast Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Diagnostic and Predictive
• Prognostic
• Research
• Others

Global Breast Cancer Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Medical Laboratories
• Others

Global Breast Cancer Diagnostics Market Size & CAGR (2025-2032)

• North America (Type, Product, Cancer Type, Application, End-user)
  • US
  • Canada
• Europe (Type, Product, Cancer Type, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Cancer Type, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Cancer Type, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Cancer Type, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hologic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (USA) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi Medical Systems (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations